RGEN — Repligen Corp
NASDAQ · Life Sciences Tools & Services · Life Sciences Tools & Services
- Latest Close
- $114.06
- 30-Day Move
- -27.5%
- Market Cap
- $6.4B
- Shares Outstanding
- 56,330,000
- P/E Ratio
- 132.53
- P/B Ratio
- 4.38
Analyst consensus: Buy · 28 analysts
Repligen Corp
A read-only Alphactor snapshot forRepligen Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$114.06
30-Day Move
-27.5%
Market Cap
$6.4B
Shares Outstanding
56,330,000
P/E Ratio
132.53
P/B Ratio
4.38
$114.06
-27.5%last 90 delayed daily bars
90D High
$175.77
90D Low
$109.50
Avg Volume
803,214
Gross margin is running at 52.6%, which gives a quick read on operating quality before you open the full model.
Net margin is 6.6%, useful for comparing RGEN against peers in Life Sciences Tools & Services.
RGEN is down 27.5% over the last 30 trading days shown on this page.
Latest operating income is $16M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$28.74
Rule of 40
28.8%
Dark Pool Short %
79.9%
Latest Close
$114.06
30-Day Move
-27.5%
Market Cap
$6.4B
Shares Outstanding
56,330,000
P/E Ratio
132.53
P/B Ratio
4.38
ROE
2.3%
ROA
1.7%
Gross Margin
52.6%
Operating Margin
7.5%
Net Margin
6.6%
Debt / Equity
0.26
Current Ratio
8.37
Latest Revenue
$198M
Revenue
$198M
Gross Profit
$104M
Operating Income
$16M
Net Income
$13M
Gross Margin
5265.0%
Net Margin
662.0%
Current Ratio
8.37
Debt / Equity
0.26
Fair Value
$28.74
Upside / Downside
-74.8%
Signal
Overvalued
Implied Growth
23.4%
DCF
$17.11
EPV
$5.78
EV/Rev
$63.33
Growth Assumption
-2.7%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$92M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Altman Z
5.50
Safe
Piotroski
8
Strong (7-9)
Cash Conversion
2.40x
Rule of 40
28.8%
Acceptable
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $802M | $196M | $186M | $39M |
| 2023-12-31 | $632M | $17M | $36M | $75M |
| 2024-12-31 | $634M | $-32M | $-26M | $142M |
| 2025-12-31 | $738M | $42M | $49M | $92M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$201,830.4
Sell Value
$16M
Buys
1
Sells
27
Buy Value
$201,830.4
Sell Value
$16M
Buy/Sell Ratio
0.04x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-21 | Loeillot Olivier | Sell | 3,832 | $140.00 |
| 2026-03-05 | Loeillot Olivier | A | 25,890 | $0.00 |
| 2026-03-05 | Loeillot Olivier | A | 24,134 | $0.00 |
| 2026-03-05 | Bylund James | A | 8,315 | $0.00 |
| 2026-03-05 | Bylund James | A | 7,751 | $0.00 |
| 2026-03-05 | Garland Jason K | A | 8,315 | $0.00 |
| 2026-03-05 | Garland Jason K | A | 7,751 | $0.00 |
| 2026-03-05 | KURIYEL RALF | A | 5,669 | $0.00 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 1,709,786 | 0.03% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1,685,677 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1,213,698 | 0.02% | 2025-12-31 |
| T. Rowe Price New Horizons Fund, Inc. | 912,483 | 0.02% | 2025-12-31 |
| MFS Series Trust IV-MFS Mid Cap Growth Fund | 866,360 | 0.02% | 2026-02-28 |
| T. Rowe Price All-Cap Opportunities Fd., Inc.-T. Rowe Price All-Cap Op | 748,455 | 0.01% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 684,844 | 0.01% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 570,114 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Two Sigma Advisers
Filed 2025-11-14
--
--
BlackRock
Filed 2024-05-10
$1.4B
--
Vanguard Group
Filed 2026-01-29
$818M
-1.0%
FMR LLC (Fidelity)
Filed 2026-02-17
$470M
+6.6%
Citadel Advisors
Filed 2026-02-17
$228M
--
Bank of New York Mellon
Filed 2026-02-10
$220M
+2.2%
4.07
Consensus
Buy—
—
—
28
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.